“…Therapy monitoring is required for drug dosage adjustment [ 10 , 11 ], especially when clearance is impaired [ 12 , 13 ], or in the presence of heparin resistance [ 14 , 15 , 16 , 17 ]. Rare and severe side effects can develop such as heparin-induced thrombocytopenia (HIT) [ 18 , 19 ]; however, heparin remains to be the anticoagulant of choice in many critical circumstances [ 1 , 8 , 20 , 21 , 22 ] and has anticoagulant activity through additional mechanisms [ 23 , 24 , 25 ]. UFH and LMWH drug dosages need to be accurately adjusted for each treated patient [ 2 , 6 , 13 , 26 , 27 ].…”